This laid the foundation for the current study that investigated whether IC administration of autologous CD34+ cells would improve cardiac function and symptoms of HF and angina in patients with diffuse CAD and relatively preserved LV systolic function unsuitable for coronary intervention. The gene discussed is CD34; the disease is hydrops fetalis.